National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 15314 [2016-06336]
Download as PDF
<![CDATA[
asabaliauskas on DSK3SPTVN1PROD with NOTICES
15314
Federal Register / Vol. 81, No. 55 / Tuesday, March 22, 2016 / Notices
exclusively in-licensed check point
inhibitor with Ad-Her2 and ME–TARP
vaccine within the Licensed Patent
Rights.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before April
6, 2016 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Sabarni K. Chatterjee, Ph.D., M.B.A.
Senior Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702 Telephone: (240)–276–
5530; Facsimile: (240)–276–5504E-mail:
chatterjeesa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This
invention concerns the identification of
immunogenic peptides within TARP,
and their use to create an anti-cancer
immune response in patients. By
introducing these peptides into a
patient, an immune response against
these cancer cells can be initiated by the
peptides, resulting in treatment of the
cancer. A phase I clinical trial in stage
D0 prostate cancer patients is nearing
completion. Initial results indicate a
statistically significant decrease in the
slope of PSA for 48 weeks after
vaccination.
Additionally, a novel vaccine
candidate using recombinant
adenoviruses expressing the
extracellular (EC) and transmembrane
(TM) domains of human HER2
(HER2ECTM) are also being developed
that is within the scope of the field of
use licensed to Midissia. The
recombinant adenovirus expresses a
chimeric fiber protein having the
adenovirus type 35 (Ad5) shaft and
knob domains, which facilitates
transduction of human dendritic cells
by the recombinant HER2ECTM
expressing adenovirus. The vaccine
candidate, namely, AdHer2ECTM) can
potentially to treat patients with Her2
expressing tumors. Clinical studies with
this adenovirus based vaccine is
currently being planned.
Both technologies have the potential
of being developed into a vaccine for
several cancer indications or for the
treatment of any cancer associated with
increased or preferential expression of
TARP and Her 2/neu.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
VerDate Sep<11>2014
17:34 Mar 21, 2016
Jkt 238001
granted unless within fifteen (15) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 16, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–06374 Filed 3–21–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIDDK.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
NATIONAL INSTITUTE OF DIABETES
AND DIGESTIVE AND KIDNEY
DISEASES, including consideration of
personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors, NIDDK
Date: April 14–15, 2016.
Open: April 14, 2016, 8:00 a.m. to 8:15 a.m.
Agenda: Introductions and Overview.
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
Place: National Institutes of Health, Porter
Neuroscience Research Center, Building 35A
Convent Drive, Rooms 620/630, Bethesda,
MD 20892.
Close: April 14, 2016, 8:15 a.m. to 4:40
p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, Porter
Neuroscience Research Center, Building 35A
Convent Drive, Rooms 620/630, Bethesda,
MD 20892.
Close: April 15, 2016, 8:00 a.m. to 4:30
p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, Porter
Neuroscience Research Center, Building 35A
Convent Drive, Rooms 620/630, Bethesda,
MD 20892.
Contact Person: Michael W. Krause, Ph.D.,
Scientific Director, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institute of Health, Building 5,
Room B104, Bethesda, MD 20892–1818, (301)
402–4633, mwkrause@helix.nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 15, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–06336 Filed 3–21–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-day
Comment Request: Cancer Genomics
Cloud Pilots Survey (NCI)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Cancer Institute (NCI), the National
Institutes of Health, has submitted to the
Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on January 13,
SUMMARY:
E:\FR\FM\22MRN1.SGM
22MRN1
]]>Agencies
[Federal Register Volume 81, Number 55 (Tuesday, March 22, 2016)]
[Notices]
[Page 15314]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-06336]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Board of Scientific Counselors, NIDDK.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the NATIONAL
INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES, including
consideration of personnel qualifications and performance, and the
competence of individual investigators, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, NIDDK
Date: April 14-15, 2016.
Open: April 14, 2016, 8:00 a.m. to 8:15 a.m.
Agenda: Introductions and Overview.
Place: National Institutes of Health, Porter Neuroscience
Research Center, Building 35A Convent Drive, Rooms 620/630,
Bethesda, MD 20892.
Close: April 14, 2016, 8:15 a.m. to 4:40 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Porter Neuroscience
Research Center, Building 35A Convent Drive, Rooms 620/630,
Bethesda, MD 20892.
Close: April 15, 2016, 8:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Porter Neuroscience
Research Center, Building 35A Convent Drive, Rooms 620/630,
Bethesda, MD 20892.
Contact Person: Michael W. Krause, Ph.D., Scientific Director,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institute of Health, Building 5, Room B104, Bethesda, MD
20892-1818, (301) 402-4633, mwkrause@helix.nih.gov.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: March 15, 2016.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-06336 Filed 3-21-16; 8:45 am]
BILLING CODE 4140-01-P
